The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

The sorafenib resistance-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma

Published:2024-01-17 Issue:2 Volume:23 Page:150-168
ISSN:1538-4101
Container-title:Cell Cycle
language:en
Short-container-title:Cell Cycle

Author:

Luo Tianxin¹²,Chen Xiaomei¹²,Pan Wei³,Zhang Shu¹²,Huang Jian¹²

Affiliation:

1. Center for Clinical Laboratories, the Affiliated Hospital of Guizhou Medical University, Guiyang, China

2. School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, China

3. Prenatal Diagnosis Center, the Affiliated Hospital of Guizhou Medical University, Guiyang, China

Funder

National Natural Science Foundation of China

Science and Technology Foundation of Guizhou Health and Family Planning Commission

Science and Technology Foundation of Traditional Chinese Medicine and Ethnic Medicine

Guizhou Science and Technology Plan Project

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/15384101.2024.2309020

Reference53 articles.

1. Disease Burden of Hepatocellular Carcinoma: A Global Perspective

2. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes

3. Targeted therapy for hepatocellular carcinoma

4. The paradigm of drug resistance in cancer: an epigenetic perspective

5. Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP